Geneart AG

Geneart AG (OJ:G6A) - Net sales increase by more than 30 % to EUR 11.7M after nine months - Operating result of EUR 1.4M reached the previous year's level - Continued strong growth of small and mid-sized orders - Preliminary results are being confirmed

Geneart AG (OJ:G6A) - GENEART is partner of the iGEM (International Genetically Engineered Machines) contest for the second year in a row - The contest for applications in Synthetic Biology is one of its kind worldwide, and took place for the fifth time - Over 84 student teams from around the world designed cells with useful properties with the help of genetic building blocks - First prizes were awarded for genetic building blocks with potential for medical applications

Geneart AG (OJ:G6A) - Historic event: "Mammalian Gene Collection" completed - For the project GENEART synthesized approx. 2,400 genes - Additional growth impulses expected for the gene synthesis market

Geneart AG (OJ:G6A) - Net sales for 2008 at EUR 11.7M after 9 months - EBIT reaches EUR 1.4M - For the entire year of 2008, net sales between EUR 15.5M and 16.5M are expected with EBIT at prior year's level - Market position was further expanded in slightly weaker market conditions

Geneart AG (OJ:G6A) - GENEART among the top 15 of the fastest growing technology companies in Germany - Among life science companies of this competition, GENEART ranks second - Cumulative corporate growth exceeds 800 percent over the past five years - Targeted investing in automation and process technologies allows further increase in capacities

Geneart AG (OJ:G6A) - Ernst & Young honours Germany's best mid-tier companies - Impressive growth rates and high innovative strength lead GENEART AG's team into the final - Prestigious business award will be presented at the Alte Oper Frankfurt on October 9, 2008.

Geneart AG (OJ:G6A) - GENEART wins "European Biotechnica Award", awarded by the Deutsche Messe AG and its partners - The award is honouring high innovative strength and a powerful business concept - The prestigious prize comprises of cash and non-cash benefits totalling EUR 100,000 - The British company Astex Therapeutics Limited and the German company immatics biotechnologies GmbH were honoured as finalists

Geneart AG (OJ:G6A) - GENEART presents the advantages of designed genes and gene synthesis in the programming of vaccines - GENEART will chair an "Industrial Biotechnology" workshop - 'Synthetic Biology 4.0' is the most important international conference on Synthetic Biology, now in its fourth year - GENEART is one of the main sponsors - With DNA synthesis, GENEART provides one of the key technologies for the Synthetic Biology

Geneart AG (OJ:G6A) - The iGEM ("International Genetically Engineered Machine") competition is the only competition of its kind. Its objective is the development of standardized DNA components for applications in Synthetic Biology - GENEART is sponsoring partner of this competition, supporting the organizers and the student teams and donating one of the main prizes - 84 Teams of students from all corners of the globe participate

Geneart AG (OJ:G6A) - GENEART increases sales activities in its key foreign market - Founding of a new sales office in San Francisco (California, USA) is completed - GENEART positions itself in the vicinity of customers on the west coast, with research budgets of more than USD 12 billion